# Uli C. Broedl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/uli-c-broedl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,090 |
| Field | Diabetes Treatment and Management |
| h-index | 62 |
| i10-index | 104 |
| Last Known Institution | Boehringer Ingelheim (United States) |
| OpenAlex ID | https://openalex.org/A5012223927 |
| ORCID iD | 0000-0001-9893-7747 |
| Works | 153 |

## Researcher papers

Showing 12 of 14.

- [Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-cardiovascular-outcomes-and-mortality-in-type-2-diabetes/)
- [Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes](https://scholariq.org/papers/empagliflozin-and-progression-of-kidney-disease-in-type-2-diabetes/)
- [Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus](https://scholariq.org/papers/renal-hemodynamic-effect-of-sodium-glucose-cotransporter-2-inhibition-in/)
- [Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients](https://scholariq.org/papers/metabolic-response-to-sodium-glucose-cotransporter-2-inhibition-in-type-2/)
- [Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial](https://scholariq.org/papers/heart-failure-outcomes-with-empagliflozin-in-patients-with-type-2-diabetes-at/)
- [Adipokines and Insulin Resistance](https://scholariq.org/papers/adipokines-and-insulin-resistance/)
- [Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/efficacy-and-safety-of-empagliflozin-added-to-existing-antidiabetes-treatment-in/)
- [Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes](https://scholariq.org/papers/effects-of-empagliflozin-on-blood-pressure-and-markers-of-arterial-stiffness-and/)
- [Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease](https://scholariq.org/papers/empagliflozin-and-clinical-outcomes-in-patients-with-type-2-diabetes-mellitus/)
- [The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus](https://scholariq.org/papers/the-effect-of-empagliflozin-on-arterial-stiffness-and-heart-rate-variability-in/)
- [Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin](https://scholariq.org/papers/combination-of-empagliflozin-and-linagliptin-as-second-line-therapy-in-subjects/)
- [The role of machine learning in clinical research: transforming the future of evidence generation](https://scholariq.org/papers/the-role-of-machine-learning-in-clinical-research-transforming-the-future-of/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)

## Researcher university

- [Boehringer Ingelheim (United States)](https://scholariq.org/institutions/boehringer-ingelheim-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.